31 December 2018
("ImmuPharma" or the "Company")
UPDATE ON NUCANT CANCER PROGRAMME
Clinical Development Collaboration with Incanthera
ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company provides an update on its clinical development collaboration agreement for its Nucant cancer programme, with Incanthera Limited ("Incanthera"), a specialist oncology development company.
As announced on 7 December 2018, ImmuPharma alongside Incanthera are making good progress in finalising the 'Definitive Licence Agreement'. It has been agreed between both companies to extend the exclusivity period, which was initially granted to 31 December 2018, to 31 March 2019, in order to finalise the remaining parts of the agreement.
It is now envisaged that the 'Definitive Licence Agreement' will be finalised in the first quarter of 2019 and as such, a further update on this collaboration will be announced in due course.
Commenting, Dimitri Dimitriou, ImmuPharma's Chief Executive Officer, said:
"We are working diligently with Incanthera's management team to finalise the last remaining parts to the 'Definitive Licence Agreement' and look forward to updating the market and shareholders in Q1 2019."
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014. ("MAR")
For further information please contact:
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.